Details of Disease

General Information of Disease (ID: DISYP8FH)

• Disease Name: Toxoplasmosis
• Synonyms: disseminated toxoplasmosis; Toxoplasma gondii infectious disease; Toxoplasma gondii caused disease or disorder; Toxoplasma gondii disease or disorder
• Disease Class: 1F57: Toxoplasmosis
• Definition: A parasitic disease contracted by the ingestion or fetal transmission of toxoplasma gondii.
• Disease Hierarchy:
  DISVU41B: Coccidiosis
  DISEM33Q: Infectious disease
  DISYP8FH: Toxoplasmosis
• ICD Code: ICD-11: ICD-11: 1F57
• Disease Identifiers:
  MONDO ID: MONDO_0005989
  MESH ID: D014123
  UMLS CUI: C0040558
  MedGen ID: 21597
  SNOMED CT ID: 187192000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Trimetrexate	DMDEA85	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
VYR 006	DMC9N7D	Phase 1	Small molecular drug	[2]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SND-226	DMZF20L	Investigative	NA	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 10 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BAX	TTQ57WJ	Limited	Biomarker	[4]
DGAT1	TT0GV3R	Limited	Biomarker	[5]
DNAJB1	TTPXAWS	Limited	Biomarker	[6]
FDPS	TTIKWV4	Limited	Biomarker	[7]
FUT3	TTUPAD7	Limited	Biomarker	[8]
TMPRSS11D	TTWHYC8	Limited	Biomarker	[9]
CD9	TTZEIBV	Strong	Biomarker	[10]
CTSC	TT4H0V2	Strong	Biomarker	[11]
DHFR	TTYZVDJ	Strong	Biomarker	[12]
P2RX7	TT473XN	Strong	Biomarker	[13]

This Disease Is Related to 15 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACO1	OT2VUR7L	Limited	Altered Expression	[14]
CENPV	OTPQ0KT9	Limited	Biomarker	[15]
CPSF3	OTS3KSNG	Limited	Biomarker	[16]
DCTN3	OTQOSUES	Limited	Biomarker	[17]
DYNC1H1	OTD1KRKO	Limited	Biomarker	[17]
GBP5	OTS4AO4A	Limited	Biomarker	[18]
GGPS1	OTVEHG28	Limited	Biomarker	[7]
HM13	OTGEO1LP	Limited	Biomarker	[19]
IMMP1L	OTA6LOLR	Limited	Biomarker	[19]
MYO1B	OTGZUJ0I	Limited	Biomarker	[20]
PLP1	OT8CM9CX	Limited	Biomarker	[21]
PSD	OTUZIXUZ	Limited	Biomarker	[22]
SKP1	OT5BPAZ4	Limited	Biomarker	[23]
CD99	OTPUZ5DE	Strong	Genetic Variation	[24]
EMP1	OTSZHUHQ	Strong	Biomarker	[25]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Clinical pipeline report, company report or official report of Vyera Pharmaceuticals.
• [3] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [4] [Effect of Toxoplasma gondii infection on thymus cells in rats].Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2013 Aug;31(4):280-3.
• [5] Novel Approaches To Kill Toxoplasma gondii by Exploiting the Uncontrolled Uptake of Unsaturated Fatty Acids and Vulnerability to Lipid Storage Inhibition of the Parasite.Antimicrob Agents Chemother. 2018 Sep 24;62(10):e00347-18. doi: 10.1128/AAC.00347-18. Print 2018 Oct.
• [6] Immunization with plasmid DNA expressing Heat Shock Protein 40 confers prophylactic protection against chronic Toxoplasma gondii infection in Kunming mice.Parasite. 2018;25:37. doi: 10.1051/parasite/2018040. Epub 2018 Jul 23.
• [7] Antiparasitic Activity of Sulfur- and Fluorine-Containing Bisphosphonates against Trypanosomatids and Apicomplexan Parasites.Molecules. 2017 Jan 4;22(1):82. doi: 10.3390/molecules22010082.
• [8] FUT3 and FUT2 genotyping and glycoconjugate profile Lewis(b) as a protective factor to Toxoplasma gondii infection.Acta Trop. 2019 May;193:92-98. doi: 10.1016/j.actatropica.2019.02.031. Epub 2019 Mar 1.
• [9] Privileged Structures in the Design of Potential Drug Candidates for Neglected Diseases.Curr Med Chem. 2019;26(23):4323-4354. doi: 10.2174/0929867324666171023163752.
• [10] Toxoplasma gondii: Protective immunity induced by a DNA vaccine expressing GRA1 and MIC3 against toxoplasmosis in BALB/c mice.Exp Parasitol. 2016 Jul;166:131-6. doi: 10.1016/j.exppara.2016.04.003. Epub 2016 Apr 6.
• [11] DNA Vaccines Encoding Toxoplasma gondii Cathepsin C 1 Induce Protection against Toxoplasmosis in Mice.Korean J Parasitol. 2017 Oct;55(5):505-512. doi: 10.3347/kjp.2017.55.5.505. Epub 2017 Oct 31.
• [12] Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.J Med Chem. 2019 Feb 14;62(3):1562-1576. doi: 10.1021/acs.jmedchem.8b01754. Epub 2019 Jan 24.
• [13] Disruption of Purinergic Receptor P2X7 Signaling Increases Susceptibility to Cerebral Toxoplasmosis.Am J Pathol. 2019 Apr;189(4):730-738. doi: 10.1016/j.ajpath.2019.01.001. Epub 2019 Jan 14.
• [14] Transferrin receptor induction in Toxoplasma gondii-infected HFF is associated with increased iron-responsive protein 1 activity and is mediated by secreted factors.Parasitol Res. 2004 Oct;94(3):233-9. doi: 10.1007/s00436-004-1209-2. Epub 2004 Sep 1.
• [15] Polymerase chain reaction approaches for the detection of Neospora caninum and Toxoplasma gondii.Int J Parasitol. 1998 Jul;28(7):1053-60. doi: 10.1016/s0020-7519(98)00096-4.
• [16] Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis.EMBO Mol Med. 2017 Mar;9(3):385-394. doi: 10.15252/emmm.201607370.
• [17] P35 and P22 Toxoplasma gondii antigens abbreviate regions to diagnose acquired toxoplasmosis during pregnancy: toward single-sample assays.Clin Chem Lab Med. 2017 Mar 1;55(4):595-604. doi: 10.1515/cclm-2016-0331.
• [18] NADPH Oxidase and Guanylate Binding Protein 5 Restrict Survival of Avirulent Type III Strains of Toxoplasma gondii in Naive Macrophages.mBio. 2018 Aug 28;9(4):e01393-18. doi: 10.1128/mBio.01393-18.
• [19] Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis.Vaccine. 2012 Mar 16;30(13):2282-7. doi: 10.1016/j.vaccine.2012.01.073. Epub 2012 Feb 3.
• [20] The Virulence-Related MYR1 Protein of Toxoplasma gondii as a Novel DNA Vaccine Against Toxoplasmosis in Mice.Front Microbiol. 2019 Apr 9;10:734. doi: 10.3389/fmicb.2019.00734. eCollection 2019.
• [21] Immuno-efficacy of DNA vaccines encoding PLP1 and ROP18 against experimental Toxoplasma gondii infection in mice.Exp Parasitol. 2018 May;188:73-78. doi: 10.1016/j.exppara.2018.04.003. Epub 2018 Apr 4.
• [22] Monitoring of visual field over 6months after active ocular toxoplasmosis.Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1481-1488. doi: 10.1007/s00417-019-04313-2. Epub 2019 Apr 29.
• [23] O(2) sensing-associated glycosylation exposes the F-box-combining site of the Dictyostelium Skp1 subunit in E3 ubiquitin ligases.J Biol Chem. 2017 Nov 17;292(46):18897-18915. doi: 10.1074/jbc.M117.809160. Epub 2017 Sep 19.
• [24] Toxoplasma gondii: DNA vaccination with genes encoding antigens MIC2, M2AP, AMA1 and BAG1 and evaluation of their immunogenic potential.Exp Parasitol. 2007 Jul;116(3):273-82. doi: 10.1016/j.exppara.2007.01.017. Epub 2007 Feb 1.
• [25] Toxoplasmosis in non-cardiac solid organ transplant recipients: A case series and review of literature.Transpl Infect Dis. 2020 Feb;22(1):e13218. doi: 10.1111/tid.13218. Epub 2019 Dec 12.